Xbrane to list on Nasdaq Stockholm

Corporate Information

English

IR

Listing Regulation

mfn-ci-other

News

Regulatory

Nasdaq Stockholm’s listing committee has decided that Xbrane Biopharma AB (publ) (”Xbrane” or the “Company) fulfills the requirements for admission to trading of the Company’s shares on the main market Nasdaq Stockholm subject to customary provisions[1].

The first day of trading of Xbrane’s shares on Nasdaq Stockholm is expected to be Monday 23 September 2019. The last day of trading of Xbrane’s shares on Nasdaq First North Growth Market is expected to be Friday 20 September 2019.

Shareholders of Xbrane do not need to take any action in connection with the change of listing venue.

The shares that will be admitted to trading on Nasdaq Stockholm will be traded under the same ticker, “XBRANE”, and with the same ISIN code SE0007789409. No new shares will be issued in connection with the listing on Nasdaq Stockholm.

“Up-listing to the main market, Nasdaq Stockholm, is an important step for Xbrane. It increases the potential investor base and thus creates greater opportunities for us to become a world-leading biosimilar developer”, says Martin Åmark, CEO Xbrane.

For further information, please refer to the prospectus prepared in connection with the listing on Nasdaq Stockholm, which is expected to be approved and registered by the Swedish Financial Supervisory Authority and be published on Xbrane’s website (www.xbrane.com) on or about 19 September 2019.

Advisors
Vator Securities is financial adviser and Baker McKenzie is legal adviser to the Company in connection with the change of listing venue

For more information, please contact:
Martin Åmark, CEO
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical that develops, manufactures and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane’s headquarter is located in Solna outside of Stockholm and the company’s in-house research and development facilities are located in Sweden and Italy. Xbrane is listed at Nasdaq First North Growth Market since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane’s certified adviser (corp@avanza.se, +46 (0)8 409 421 20). For more information *please visit  www.xbrane.com.*

[1] The approval is subject to customary conditions, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority and confirmation that the dispersion requirements in respect of the shares are fulfilled.